Physician profile
Mark Harmon
NPI 1932102290
$4,631.59
in general payments reported to CMS, 2019-2025
14 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $265 · 2021: $283 · 2022: $405 · 2023: $792 · 2024: $1,492 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540 · Long Term Medical Supply Or Device Loan: $560 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.40 |
| Long Term Medical Supply Or Device Loan | $560.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $1,289.90 | 2024-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $973.50 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Alcon Vision LLC | $914.07 | 2019-2025 | Lensx, Centurion, Clareon |
| Allergan, INC. | $362.97 | 2019-2022 | |
| Abbvie INC. | $357.20 | 2022-2024 | |
| Beaver-Visitec International, INC. | $270.59 | 2020-2023 | |
| Rxsight INC | $150.29 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $104.59 | 2025 | Envista Envy Iol, Xiidra, Miebo |
| Dompe US, INC. | $52.32 | 2025 | Oxervate |
| Harrow Eye, LLC | $51.56 | 2025 | Iheezo, Triesence |
| Glaukos Corporation | $40.95 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $29.08 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $20.01 | 2023 | |
| Aerie Pharmaceuticals, INC. | $14.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.